R057: Interstitial Infusion Catheters in Intratumoral Chemotherapy

2007 ◽  
Vol 137 (2_suppl) ◽  
pp. P169-P169
Author(s):  
Vivian M Yu ◽  
Carrie Flanagan ◽  
Rick Odland
Keyword(s):  
Intratumoral Chemotherapy ◽  
Interstitial Infusion

Role of renal medullary adenosine in the control of blood flow and sodium excretion

1999 ◽  
Vol 276 (3) ◽  
pp. R790-R798 ◽  
Author(s):  
Ai-Ping Zou ◽  
Kasem Nithipatikom ◽  
Pin-Lan Li ◽  
Allen W. Cowley
Keyword(s):  
Blood Flow ◽  
Sodium Excretion ◽  
Renal Medulla ◽  
Urine Flow ◽  
Doppler Flowmetry ◽  
Blood Flows ◽  
Medullary Blood Flow ◽  
Adenosine Concentration ◽  
Interstitial Infusion

This study determined the levels of adenosine in the renal medullary interstitium using microdialysis and fluorescence HPLC techniques and examined the role of endogenous adenosine in the control of medullary blood flow and sodium excretion by infusing the specific adenosine receptor antagonists or agonists into the renal medulla of anesthetized Sprague-Dawley rats. Renal cortical and medullary blood flows were measured using laser-Doppler flowmetry. Analysis of microdialyzed samples showed that the adenosine concentration in the renal medullary interstitial dialysate averaged 212 ± 5.2 nM, which was significantly higher than 55.6 ± 5.3 nM in the renal cortex ( n = 9). Renal medullary interstitial infusion of a selective A1antagonist, 8-cyclopentyl-1,3-dipropylxanthine (DPCPX; 300 pmol ⋅ kg−1 ⋅ min−1, n = 8), did not alter renal blood flows, but increased urine flow by 37% and sodium excretion by 42%. In contrast, renal medullary infusion of the selective A2 receptor blocker 3,7-dimethyl-1-propargylxanthine (DMPX; 150 pmol ⋅ kg−1 ⋅ min−1, n = 9) decreased outer medullary blood flow (OMBF) by 28%, inner medullary blood flows (IMBF) by 21%, and sodium excretion by 35%. Renal medullary interstitial infusion of adenosine produced a dose-dependent increase in OMBF, IMBF, urine flow, and sodium excretion at doses from 3 to 300 pmol ⋅ kg−1 ⋅ min−1( n = 7). These effects of adenosine were markedly attenuated by the pretreatment of DMPX, but unaltered by DPCPX. Infusion of a selective A3receptor agonist, N 6-benzyl-5′-( N-ethylcarbonxamido)adenosine (300 pmol ⋅ kg−1 ⋅ min−1, n = 6) into the renal medulla had no effect on medullary blood flows or renal function. Glomerular filtration rate and arterial pressure were not changed by medullary infusion of any drugs. Our results indicate that endogenous medullary adenosine at physiological concentrations serves to dilate medullary vessels via A2 receptors, resulting in a natriuretic response that overrides the tubular A1 receptor-mediated antinatriuretic effects.

scholarly journals Intratumoral chemotherapy for lung cancer: re-challenge current targeted therapies

2013 ◽  
pp. 571 ◽  
Author(s):  
Paul Zarogoulidis ◽  
Darwiche ◽  
Celikoglu ◽  
Francis Turner ◽  
Konstantinos Zarogoulidis ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Targeted Therapies ◽  
Intratumoral Chemotherapy

scholarly journals Acute Renal Medullary Interstitial Infusion of either saline or 2% albumin indistinctly rises RIHP and RMBF in the rat

2013 ◽  
Vol 27 (S1) ◽  
Author(s):  
Maria Eugenia Sánchez‐Briones ◽  
Juan Francisco López‐Rodríguez ◽  
Miriam Zarahí Calvo‐Turrubiartes ◽  
Manuel Rodríguez‐Martínez
Keyword(s):  
Interstitial Infusion

Effect of renal interstitial infusion of arachidonic acid on proximal sodium reabsorption

1989 ◽  
Vol 257 (2) ◽  
pp. F237-F242 ◽  
Author(s):  
Y. Kinoshita ◽  
J. C. Romero ◽  
F. G. Knox
Keyword(s):  
Arachidonic Acid ◽  
Urinary Excretion ◽  
Proximal Tubules ◽  
Sodium Reabsorption ◽  
Renal Interstitium ◽  
Tubular Sodium Reabsorption ◽  
Proximal Tubular ◽  
The Individual ◽  
Stimulation Of ◽  
Interstitial Infusion

The effect of prostaglandins (PGs) on proximal sodium reabsorption has not been fully defined. The objective of the present study was to determine the response of proximal tubular sodium reabsorption to infusions of arachidonic acid and specific PGs into the renal interstitium in rats. Renal interstitial infusions of arachidonic acid as well as the individual PGs, I2, E2, and F2 alpha, were employed to elevate the concentration of these PGs in the kidney. Infusion of 10(-4) M arachidonic acid elicited a marked increase of urinary excretion of 6-keto-PGF1 alpha (a stable metabolite of PGI2) from 260.1 +/- 52.7 to 507.4 +/- 129.5 pg/min (P less than 0.05) and a smaller increase of PGE2 from 18.4 +/- 11.2 to 25.9 +/- 10.9 pg/min (P less than 0.05). When micropuncture samples were obtained from superficial late proximal tubules, infusion of arachidonic acid increased the fractional delivery of sodium (FDNa) from 47.8 +/- 5.9 to 58.3 +/- 4.6% (n = 6, P less than 0.01). In the presence of indomethacin, arachidonic acid failed to augment FDNa. Infusion of 10(-5) M PGI2 also increased FDNa from 51.4 +/- 3.4 to 64.0 +/- 4.4% (n = 10, P less than 0.01). PGF2 alpha did not change FDNa and PGE2 decreased it from 53.1 +/- 5.4 to 37.4 +/- 3.3% (n = 8, P less than 0.01). In summary, the present study demonstrates that renal interstitial infusion of arachidonic acid decreases sodium reabsorption by the superficial proximal tubules possibly through the stimulation of PGI2 production.

scholarly journals Resensitization to Nivolumab after Intratumoral Chemotherapy in Recurrent Head and Neck Squamous Cell Cancer: A Report of 2 Cases

2020 ◽  
Vol 13 (2) ◽  
pp. 835-842
Author(s):  
Aline Houessinon ◽  
Aurélie Moreira ◽  
Jérèmie Bettoni ◽  
Marine Schoonaker ◽  
Chloé Sauzay ◽  
...  
Keyword(s):  
Head And Neck ◽  
Squamous Cell ◽  
Response Rate ◽  
Squamous Cell Cancer ◽  
Checkpoint Inhibitors ◽  
Cell Cancer ◽  
Objective Response ◽  
Prospective Trial ◽  
Intratumoral Chemotherapy ◽  
Neck Squamous Cell Cancer

The survival of patients with head and neck squamous cancer with locoregional recurrence is short if salvage surgery or radiation cannot be performed. Systemic chemotherapy based on platinum salts and cetuximab produces only partial and transient responses. Immune checkpoint inhibitors (i.e., nivolumab) lead to a low complete response rate of only about 10%, but in some cases the effects can be long-lasting. Intratumoral chemotherapy (ITC) has been proposed for patients with local recurrence of head and neck squamous cell carcinoma with an objective response rate of 27–50%. However, it often leads to peritumoral tissue necrosis, and the duration of local control is limited. Here, we present 2 patients with head and neck squamous cell cancer whose local recurrences were refractory to intravenous chemotherapy and nivolumab. ITC using nonnecrotizing molecules, associated with nivolumab, led to complete stable local and distant response. ITC seems to trigger tumor resensitization to previously ineffective immunotherapy. This combination deserves an evaluation in the framework of a prospective trial.

Prolonged stimulation of intrarenal V1 vasopressin receptors results in sustained hypertension

1994 ◽  
Vol 267 (5) ◽  
pp. R1217-R1225 ◽  
Author(s):  
E. Szczepanska-Sadowska ◽  
K. Stepniakowski ◽  
M. M. Skelton ◽  
A. W. Cowley
Keyword(s):  
Arterial Pressure ◽  
Intravenous Administration ◽  
Plasma Osmolality ◽  
Sprague Dawley ◽  
Sustained Hypertension ◽  
Body Sodium ◽  
Chronic Infusion ◽  
Vasopressin Receptors ◽  
Stimulation Of ◽  
Interstitial Infusion

In an earlier study, we reported that chronic intravenous administration of the V1 agonist [Phe2,Ile3,Orn8]vasopressin (V1AG) results in sustained hypertension. The present study was designed to determine whether V1-induced hypertension may be related specifically to intrarenal actions of this peptide. Chronic infusion of the V1 agonist into the medullary interstitial space of a single remaining kidney of normal, conscious Sprague-Dawley rats at the rate of 2 ng.kg-1.min-1 for 14 days resulted in a sustained rise of 18 mmHg of mean arterial pressure (MAP). After withdrawal of V1AG, MAP returned to the baseline level. During the first day of V1AG infusion, there was a net loss of body sodium and no evidence of fluid retention throughout the period of hypertension. Plasma osmolality, sodium and potassium concentration, and water intake and body weight were not significantly affected by medullary interstitial infusion of V1AG. Renal medullary interstitial infusion of an equimolar amount of arginine vasopressin (AVP) did not affect MAP. Chronic medullary interstitial infusion of the selective V1 antagonist d(CH2)5[Tyr(Me)2,Ala-NH(2)9]AVP in equimolar amounts (2.5 ng.kg-1.min-1) prevented the MAP increase elicited by intravenous V1AG. However, intravenous administration of the V1 antagonist at the same rate together with V1AG (n = 7) failed to prevent hypertension. The results indicate that hypertension can be elicited by chronic stimulation of renal medullary V1 vasopressin receptors. They also suggest that some V2 agonistic properties of AVP may restrict the hypertensive action of this hormone. The mechanism for the rise of arterial pressure remains to be determined.

Fine Needle Percutaneous Intratumoral Chemotherapy under Ultrasound Guidance: A Feasibility Study

1986 ◽  
Vol 72 (1) ◽  
pp. 81-87 ◽  
Author(s):  
Tito Livraghi ◽  
Emilio Bajetta ◽  
Luigi Matricardi ◽  
Eugenio Villa ◽  
Roberta Lovati ◽  
...  
Keyword(s):  
Feasibility Study ◽  
Ultrasound Guidance ◽  
Fine Needle ◽  
Intratumoral Chemotherapy

Mechanism of prostaglandin E2-induced increase of proximal sodium reabsorption in the rat

1990 ◽  
Vol 258 (1) ◽  
pp. R82-R86 ◽  
Author(s):  
Y. Kinoshita ◽  
F. G. Knox
Keyword(s):  
Angiotensin Ii ◽  
Prostaglandin E2 ◽  
Rat Kidney ◽  
Sodium Reabsorption ◽  
Sprague Dawley ◽  
Sprague Dawley Rats ◽  
Convoluted Tubules ◽  
Stimulation Of ◽  
Interstitial Infusion

Prostaglandin E2, when infused directly into the renal interstitium, enhances sodium reabsorption by the superficial proximal convoluted tubules of anesthetized Sprague-Dawley rats. The present study was designed to investigate the role of angiotensin II in the prostaglandin E2-induced stimulation of proximal sodium reabsorption. Micropuncture at the superficial late proximal tubule demonstrated a significant increase in the fractional reabsorption of sodium from 39.9 +/- 2.3% in control conditions to 51.8 +/- 3.0% (n = 9, P less than 0.01) during the renal interstitial infusion of prostaglandin E2. The stimulatory effect of prostaglandin E2 on proximal sodium reabsorption was markedly attenuated by pretreatment with saralasin. During intravenous saralasin infusion, prostaglandin E2 did not significantly change the fractional reabsorption of sodium from 42.2 +/- 5.8 to 45.4 +/- 6.0% (n = 7, NS). In summary, the stimulatory effect of renal interstitial infusion of prostaglandin E2 on proximal sodium reabsorption was attenuated by pretreatment with saralasin. Therefore renal interstitial infusion of prostaglandin E2 may enhance proximal sodium reabsorption, at least in part, through stimulation of angiotensin II production in the rat kidney.

scholarly journals Cystic craniopharyngioma: intratumoral chemotherapy with alpha interferon

2011 ◽  
Vol 69 (1) ◽  
pp. 50-55 ◽  
Author(s):  
Patrícia Alessandra Dastoli ◽  
Jardel Mendonça Nicácio ◽  
Nasjla Saba Silva ◽  
Andrea Maria Capellano ◽  
Silvia R.C. Toledo ◽  
...  
Keyword(s):  
Side Effects ◽  
Interferon Alpha ◽  
Tumor Volume ◽  
Response To Treatment ◽  
Lower Percentage ◽  
Intratumoral Chemotherapy ◽  
Cystic Craniopharyngioma ◽  
Tumor Reduction ◽  
One Year

OBJECTIVE: To assess whether the cystic craniopharyngiomas can be controlled with the use of intratumoral applications of interferon alpha. METHOD: Nineteen patients with the diagnosis of cystic craniopharyngioma were treated with intratumoral chemotherapy with interferon alpha from January 2002 to April 2006. All patients underwent placement of an intracystic catheter connected to an Ommaya reservoir. Through this reservoir were made applications during chemotherapy cycles. Each cycle corresponded to application of 3,000,000 units of interferon alpha three times per week on alternate days totalizing 36,000,000 units. Response to treatment was evaluated by calculating the tumor volume on MRI control after one, three and six months after the end of each cycle. Patients who developed worsening of symptoms or who had insignificant reduction in tumor volume during follow-up underwent repeat cycle chemotherapy. RESULTS: Four patients received four cycles of chemotherapy, three patients received three cycles, six patients received two cycles and six patients received one. The lower percentage of reduction in tumor volume was 60% and the bigger reduction was 98.37%. Eleven patients had a reduction greater than 90%. Five patients had a tumor reduction between 75 and 90% and in three patients the tumors were reduced by less than 75%. No deaths occurred during treatment and side effects of interferon alpha were well tolerated. No treatment was discontinued. Follow-up after the last application ranged from one year and five months to three years and nine months. CONCLUSION: The intratumoral chemotherapy with interferon alpha decreases the volume of cystic craniopharyngiomas and so far can be considered a new therapeutic alternative.

Sign in / Sign up

Export Citation Format

Share Document